iSpecimen gets Nasdaq extension to Nov 25, 2026 to regain equity compliance

iSpecimen Inc.

Received Nasdaq deficiency letter on Sept 8, 2026; extension to Nov 25, 2026 to meet Rule 5550(b) minimum $2.5M stockholders' equity.
Prior notice May 29, 2026; compliance plans submitted July 13, Aug 6, Sept 4, 2026.
Private placement closed May 11, 2026 raised ~$2.5M; planned best-efforts public offering of ~$5M.
Projected stockholders' equity ~$5.1M through June 30, 2027; delisting risk if not compliant by year-end 2026 report.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.